EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine
Biotech

EMA approves Pfizer’s 20-valent pneumococcal conjugate vaccine

Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia

  • By IPP Bureau | February 16, 2022

Pfizer announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name Apexxnar. The vaccine is approved for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumonia in individuals 18 years of age and older.

“The EMA’s authorization of Apexxnar for adults continues Pfizer’s ongoing commitment to help prevent certain potentially-serious infectious respiratory diseases, including invasive pneumococcal disease and pneumonia,” said Nanette Cocero, Ph.D., Global President of Pfizer Vaccines. “Apexxnar helps protect against the 20 serotypes in the vaccine, and today’s approval offers adults -- through a single dose -- the broadest serotype protection of any available pneumococcal conjugate vaccine in Europe.”

The authorization is valid in all 27 EU member states plus Iceland, Lichtenstein, and Norway.

Upcoming E-conference

Other Related stories

Startup

Digitization